SCHEMBL5547196

SCHEMBL5547196

CC(C)Oc1ccc(CN[C]=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
NR1H4 Q96RI1 1/20 0.48
TP53 P04637 1/20 0.46
ACACB O00763 4/20 0.44
KDM4C Q9H3R0 1/20 0.44
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GLA P06280 1/20 0.43
ALDH1A3 P47895 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
MITF O75030 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537784 0.80 HDAC4 (0.44) ALDH1A1LMNANPC1RAB9AACACB
SCHEMBL1987105 0.79 ALDH1A1 (0.52) ALDH1A1NPC1RAB9AGAASMN1; SMN2
SCHEMBL895308 0.77 ALDH1A1 (0.56) POLBALDH1A1LMNANPC1RAB9A
SCHEMBL5540203 0.76 NQO1 (0.52) POLBALDH1A1LMNANPC1RAB9A
SCHEMBL25138640 0.76 ALDH1A1 (0.58) POLBALDH1A1LMNANPC1RAB9A
SCHEMBL4573921 0.76 ALDH1A1 (0.54) POLBALDH1A1LMNANPC1RAB9A
SCHEMBL3307125 0.76 RAB9A (0.46) ALDH1A1NPC1RAB9ATP53ACACB
SCHEMBL5547197 0.75 ALDH1A3 (0.52) POLBALDH1A1LMNANPC1RAB9A
SCHEMBL5535542 0.74 SMN1; SMN2 (0.51) ALDH1A1LMNAKDM4ESMN1; SMN2
SCHEMBL16257783 0.74 PYCR1 (0.56) POLBALDH1A1LMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 POLB 1637/4885ALDH1A1 355/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.